- Home
- MULN vs PMCB Comparison
MULN vs PMCB Comparison
Compare MULN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- PMCB
- Stock Information
- Founded
- MULN 2014
- PMCB 1996
- Country
- MULN United States
- PMCB United States
- Employees
- MULN N/A
- PMCB N/A
- Industry
- MULN Auto Manufacturing
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MULN Consumer Discretionary
- PMCB Health Care
- Exchange
- MULN Nasdaq
- PMCB Nasdaq
- Market Cap
- MULN 6.5M
- PMCB 7.6M
- IPO Year
- MULN N/A
- PMCB N/A
- Fundamental
- Price
- MULN $0.62
- PMCB $1.05
- Analyst Decision
- MULN
- PMCB
- Analyst Count
- MULN 0
- PMCB 0
- Target Price
- MULN N/A
- PMCB N/A
- AVG Volume (30 Days)
- MULN 8.0M
- PMCB 8.5K
- Earning Date
- MULN 08-11-2025
- PMCB 08-12-2025
- Dividend Yield
- MULN N/A
- PMCB N/A
- EPS Growth
- MULN N/A
- PMCB N/A
- EPS
- MULN N/A
- PMCB 1.29
- Revenue
- MULN $8,931,612.00
- PMCB N/A
- Revenue This Year
- MULN N/A
- PMCB N/A
- Revenue Next Year
- MULN N/A
- PMCB N/A
- P/E Ratio
- MULN N/A
- PMCB $0.82
- Revenue Growth
- MULN 2136.62
- PMCB N/A
- 52 Week Low
- MULN $0.59
- PMCB $1.00
- 52 Week High
- MULN $154,200,000.00
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- MULN 20.72
- PMCB 47.26
- Support Level
- MULN $1.62
- PMCB $1.00
- Resistance Level
- MULN $1.64
- PMCB $1.07
- Average True Range (ATR)
- MULN 0.91
- PMCB 0.05
- MACD
- MULN 152.97
- PMCB 0.01
- Stochastic Oscillator
- MULN 0.66
- PMCB 39.78
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.